Thermaiscan offers a pocket-sized breast cancer pre‑screening tool that combines off‑the‑shelf thermal imaging sensors with proprietary AI analysis. The solution enables non‑specialist healthcare workers to capture thermal images on a smartphone and receive an immediate risk assessment, facilitating early detection in primary care and remote settings. It is delivered as a scalable SaaS product, providing a cost‑effective, non‑invasive triage method for low‑resource environments.
Funding
Funding not disclosed
Founders
Product
Problem
Late detection is a critical factor in breast cancer mortality, particularly in low- and middle-income countries where access to traditional screening methods like mammography is limited. Traditional screening methods often require specialized equipment and trained specialists, creating barriers to widespread and frequent screenings.
Solution
Thermaiscan offers a mobile pre-screening solution that uses thermal imaging and AI to identify potential abnormalities in breast tissue. The solution combines thermal sensor technology with proprietary AI algorithms to analyze breast health based on metabolic activity and temperature variations captured via a smartphone. This allows healthcare professionals, including those in primary care and remote settings, to conduct quick, non-invasive risk assessments without the need for specialized equipment or expertise. The AI provides a risk assessment, flagging cases that warrant further investigation by a specialist, thereby facilitating earlier detection and intervention.
Target Audience
The primary target audience includes healthcare professionals in primary care, mini-clinics, and remote doctor settings, particularly in regions with limited access to mammography, as well as health systems looking for scalable pre-screening tools.
Features
- Smartphone-based thermal imaging for capturing breast tissue temperature variations
- Proprietary AI algorithms for image analysis and risk assessment
- Integration with off-the-shelf thermal sensors (e.g., CAT S62 Pro)
- Risk assessment output: "No Risk" or "Risk of cancer development"
- Clinical validation demonstrating 89% sensitivity and 83% specificity compared to mammography when combined with patient-reported or clinical symptoms
- Cloud-based platform for data analysis and storage
- Integration with community education platforms for premium healthcare content